BioPharma Credit PLC Result of AGM (0607B)

TIDMBPCR

RNS Number : 0607B

BioPharma Credit PLC

30 May 2023

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF 2023 ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed by way of a poll.

 
                                  Votes         %                        %   Votes Withheld(1) 
 Resolutions                        For             Votes Against 
 1: To receive 
  and accept the 
  annual report 
  and financial 
  statements                584,028,016   100.00%               0    0.00%                   0 
                           ------------  --------  --------------  -------  ------------------ 
 2: To approve 
  the Directors' 
  Remuneration Report       583,832,967    99.98%         132,056    0.02%              62,993 
                           ------------  --------  --------------  -------  ------------------ 
 3: To re-elect 
  Harry Hyman as 
  a Director                509,140,483    87.18%      74,848,533   12.82%              39,000 
                           ------------  --------  --------------  -------  ------------------ 
 4: To re-elect 
  Colin Bond as 
  a Director                583,961,133   100.00%          22,183    0.00%              44,700 
                           ------------  --------  --------------  -------  ------------------ 
 5: To re-elect 
  Duncan Budge as 
  a Director                506,318,657    86.70%      77,664,659   13.30%              44,700 
                           ------------  --------  --------------  -------  ------------------ 
 6: To re-elect 
  Stephanie Léouzon 
  as a Director             583,960,840   100.00%          22,476    0.00%              44,700 
                           ------------  --------  --------------  -------  ------------------ 
 7: To re-elect 
  Rolf Soderstrom 
  as a Director             583,977,236   100.00%           6,080    0.00%              44,700 
                           ------------  --------  --------------  -------  ------------------ 
 8: To elect Sapna 
  Shah as a Director        583,973,133   100.00%           8,683    0.00%              46,200 
                           ------------  --------  --------------  -------  ------------------ 
 9: To re-appoint 
  Ernst & Young 
  LLP as Auditor 
  to the Company            572,909,389    98.10%      11,112,627    1.90%               6,000 
                           ------------  --------  --------------  -------  ------------------ 
 10: To authorise 
  the Directors 
  to determine the 
  remuneration of 
  the Auditor               583,954,933   100.00%          20,060    0.00%              53,023 
                           ------------  --------  --------------  -------  ------------------ 
 11: To approve 
  the Company's 
  dividend payment 
  policy                    573,028,016    98.12%      11,000,000    1.88%                   0 
                           ------------  --------  --------------  -------  ------------------ 
 12: To authorise 
  the allotment 
  of shares by the 
  Company                   582,922,005   100.00%          25,280    0.00%           1,080,731 
                           ------------  --------  --------------  -------  ------------------ 
 13: To authorise 
  the disapplication 
  of pre-emption 
  rights                    556,590,025    95.48%      26,367,212    4.52%           1,070,779 
                           ------------  --------  --------------  -------  ------------------ 
 14: To authorise 
  the Company to 
  make market purchases 
  of ordinary shares        509,047,631    87.32%      73,929,283   12.68%           1,051,102 
                           ------------  --------  --------------  -------  ------------------ 
 15: To authorise 
  the Company to 
  hold general meetings 
  on 14 clear days' 
  notice                    583,949,781    99.99%          78,235    0.01%                   0 
                           ------------  --------  --------------  -------  ------------------

1. A 'vote withheld' is not a vote under English law and is not counted in the calculation of votes 'for' or 'against' a resolution.

Copies of resolutions 12 to 15 have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

30 May 2023

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

T. +44 (0) 333 300 1950

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSDMFLSEDSESI

(END) Dow Jones Newswires

May 30, 2023 10:08 ET (14:08 GMT)

Biopharma Credit (LSE:BPCP)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024